2. Academic Validation
  3. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

  • J Hematol Oncol. 2017 Jan 11;10(1):13. doi: 10.1186/s13045-016-0380-0.
Kurt Schönfeld 1,  Chantal Zuber 1,  Jan Pinkas 2,  Thomas Häder 1,  Katrin Bernöster 1,  Christoph Uherek 3
Affiliations

Affiliations

  • 1 Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
  • 2 ImmunoGen Inc., 830 Winter Street, Waltham, 02451-1477, MA, USA.
  • 3 Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany. christoph.uherek@biotest.com.
PMID: 28077160 DOI: 10.1186/s13045-016-0380-0
Abstract

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.

Keywords

Drug combination; Indatuximab ravtansine; Multiple myeloma; Pre-clinical; Tumour regression.

Figures
Products